Quick Answer
Marker Therapeutics, Inc. reported R&D Expense of $11.80 million for fiscal year 2025.
Marker Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $11.80M | -12.4% |
| 2024 | $13.47M | +29.3% |
| 2023 | $10.42M | -13.0% |
| 2022 | $11.97M | -56.9% |
| 2021 | $27.79M | +47.2% |
| 2020 | $18.88M | +47.9% |
| 2019 | $12.76M | +60.5% |
| 2018 | $7.95M | +51.5% |
| 2017 | $5.25M | +38.2% |
| 2016 | $3.80M | +122.1% |
| 2015 | $1.71M | +805.4% |
| 2014 | $189.0K | -72.9% |
| 2013 | $697.6K | -34.0% |
| 2012 | $1.06M | +419.0% |
| 2011 | $203.7K | -29.8% |
| 2010 | $290.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.35M | -32.4% | -43.8% |
| June 30, 2025 | $4.18M | +78.9% | +33.2% |
| March 31, 2025 | $3.14M | +21.8% | -9.7% |
| September 30, 2024 | $3.47M | +69.7% | +48.6% |
| June 30, 2024 | $2.34M | -1.8% | -9.3% |
| March 31, 2024 | $2.58M | -23.7% | +25.9% |
| September 30, 2023 | $2.04M | -43.1% | -14.0% |
| June 30, 2023 | $2.38M | -18.7% | -29.6% |
- Marker Therapeutics, Inc. showed a decrease of -12.4% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, Marker Therapeutics, Inc.’s r&d expense has grown by 3968.0% (from $290.0 thousand to $11.80 million).
- The most recent figure is from Marker Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: